Target intelligence / Profile preview

RUN and FYVE domain-containing protein 2 (RUFY2)

Target
RUFY2
Molecular classification
Other (multidomain regulatory protein), Adaptor protein (cytoskeletal/endosomal trafficking), Contains RUN domain (GTPase/adaptor domain), Contains FYVE zinc finger domain (endosomal membrane targeting), Member of RUFY family of proteins
01

Overview

RUN and FYVE domain-containing protein 2 (RUFY2) is a multidomain regulatory protein comprised of an N-terminal RUN domain, two central coiled-coil domains, and a C-terminal FYVE zinc finger domain. It is found predominantly in the cytoplasm and nucleus, where it regulates intracellular vesicle trafficking, endocytosis, and cytoskeletal network dynamics through interactions with small GTPases such as Rab33A, and potentially binds phosphatidylinositol-3-phosphate at endosomal membranes. RUFY2 participates in autophagy, is modulated by microRNAs (miR-155), and is frequently mutated in certain cancers, suggesting roles in cellular homeostasis, cancer, neurodegeneration, and immunity, although it is not yet established as a direct therapeutic target. The protein does not have transmembrane domains or signal peptides, but binds to partners via its RUN and FYVE domains and SH3-binding sites.

Other names
KIAA1537RABIP4RFLJ10063ZFYVE13Rab4-interacting protein relatedantigen MU-RMS-40.17Run- and FYVE-domain containing protein
02

Mechanism of action

No specific mechanisms, as no therapeutics directly target RUFY2. Regulatory modulation may be indirect, e.g., via miR-155 influencing RUFY2 expression in immune processes.

03

Biological functions

Endocytosis and endosomal membrane traffickingAutophagy regulationSignal transduction (via small GTPases, e.g., Rab33A)Cytoskeleton dynamicsNuclear function in early embryogenesisPossible transcriptional regulation (embryonic development)SH3 domain binding (protein–protein interactions)
04

Disease associations

Cancer (frequent mutational alteration in cancer cells, can lead to nonsense-mediated decay)Neurodegenerative disease (implicated by altered expression/function)Likely roles in other conditions where endocytosis/autophagy/cytoskeleton regulation is critical, but direct causal links are still emerging
05

Safety considerations

Not applicable, since RUFY2 is not a direct therapeutic target.Functional perturbation could disrupt endocytosis, autophagy, signaling, and cell migration, impacting homeostasis and contributing to disease pathogenesis when mutated or dysregulated
06

Biomarkers

RUFY2 expression and mutation pattern may be biomarker candidates in cancer, subject to further validationNo validated clinical biomarkers in current use.

Beyond the preview

Go deeper on RUN and FYVE domain-containing protein 2 (RUFY2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RUN and FYVE domain-containing protein 2 (RUFY2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call